Prednisolone — Drug Intelligence | 119 EU Trials

Filter these 119 trials by condition, phase, country and more.

Open in Search →

119 Registered trials

47 Recruiting

57 Completed trials

81 Sponsors

25 Countries

Phase III

Phase II

Phase IV

Phase III: 55 Phase II/III: 7 Phase II: 25 Phase I/II: 7 Phase III/IV: 4 Phase IV: 14 Phase I (FiH): 7

Oversight events:

7 serious breaches 48 temporary halts 2 urgent safety measures 4 unexpected events 2 corrective measures across 19 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 8 Prostate cancer metastatic 3 Myasthenia gravis 2 Giant cell arteritis 2 Dermatomyositis 2 Crigler-Najjar syndrome 2 Follicle centre lymphoma follicular grade I II III 2 Polymyositis 2 Asthma 2 Burkitt's lymphoma 1 COVID-19 1 Diffuse large B-cell lymphoma refractory 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 11 Assistance Publique Hopitaux De Paris 8 AstraZeneca AB 4 Centre Hospitalier Universitaire De Nantes 3 Fondazione Italiana Linfomi Ets 3 Genethon 3 Karolinska University Hospital 3 Pfizer Inc. 3 Ultragenyx Pharmaceutical Inc. 3 AbbVie Deutschland GmbH & Co. KG 2 Astellas Pharma Global Development Inc. 2 F. Hoffmann-La Roche AG 2

All trials — page 5

119 total

HOVON 127 BL / SAKK 37/16: Phase III study comparing 2 treatments (R-CODOX-M/R-IVAC versus DA-EPOCH-R) in patients with Burkitt lymphoma Ended

2023-503423-25-00 Phase III 2 countries Haemato Oncology Foundation For Adults Netherlands
Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement Halted

2024-519620-24-01 Phase III 1 country Centre Hospitalier Universitaire De Toulouse
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Halted

2022-500783-35-00 Phase III 6 countries GPOH gGmbH
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID Ended

2023-506949-27-00 Phase II 1 country Odense University Hospital
CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS Ended

2024-515164-30-00 Phase IV 1 country Oslo University Hospital HF
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended

2023-506250-20-00 Phase III 8 countries InflaRx GmbH
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidne… Ended

2023-503336-41-00 Phase II 3 countries Eledon Pharmaceuticals Inc.
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended

2023-505880-35-00 Phase II/III 1 country ROXALL Medizin GmbH
Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended

2023-505567-37-00 Phase II/III 1 country ROXALL Medizin GmbH
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended

2022-500121-33-01 Phase III 12 countries Hansa Biopharma AB
A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Nega… Ended

2024-512451-20-00 Phase II/III 1 country Klinikum der Universitaet Muenchen AöR
Pragmatic, randomized, multicentric, double-blind, controlled clinicial trial on the treatment of acute gout attacks with prednisolone versu… Ended

2024-514738-18-00 Phase IV 1 country Universitaetsmedizin Greifswald KöR
Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in postacute inFLAMmatory cardiac involvEment due to COVID… Ended

2024-516463-84-00 Phase III 2 countries Goethe University Frankfurt
A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm… Ended

2024-513658-31-00 Phase II 5 countries AudioCure Pharma GmbH
A trial of prednisolone in combination with SPI-62 or placebo in participants with polymyalgia rheumatica (PMR) Ended

2024-517406-29-00 Phase II 2 countries Sparrow Pharmaceuticals Inc.
An Phase 3 clinical study comparing a vector transferring the gene for Glucose-6-Phosphatase with placebo in adults with Glycogen Storage Di… Ended

2023-508750-25-00 Phase III 5 countries Ultragenyx Pharmaceutical Inc.
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed Ended

2022-501615-14-00 Phase II 4 countries Merck Sharp & Dohme LLC
A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti thymocyte … Ended

2023-507895-36-00 Phase II 3 countries Itb-Med AB
"A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended

2023-505787-11-00 Phase III 6 countries AstraZeneca AB
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S… Ended

2023-505786-88-00 Phase III 5 countries Astrazeneca AB
This is a randomized, double-blinded, Placebo controlled trial that will evaluate the potential of tildacerfont to reduce glucocorticoid use… Ended

2023-503771-13-00 Phase II 12 countries Spruce Biosciences Inc.
OPTIMIZE Ended

2024-516509-22-00 Phase IV 2 countries Universitair Medisch Centrum Groningen
A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended

2023-505476-29-00 Phase III 10 countries AbbVie Deutschland GmbH & Co. KG

Showing 97–119 of 119 trials

← All drugs A–Z